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Abstract To recommend an approach to monitoring and
treating hyperglycemia in pasireotide-treated patients with
Cushing’s disease, a severe clinical condition caused by a
pituitary adenoma hypersecreting adrenocorticotropic hor-
mone. Advisory Board meeting of ten European experts in
pituitary disease and diabetes mellitus in Munich, Germany, on
February 23, 2012, to obtain expert recommendations. Cush-
ing’s disease presents a number of management challenges.
Pasireotide, a novel agent for the treatment of Cushing’s disease
with proven biochemical and clinical efficacy, improves out-
comes and expands treatment options. Clinical trials have
shown that the pasireotide adverse event profile is similar to that
of other somatostatin analogs, except for a higher frequency of
hyperglycemia. Mechanistic studies in healthy volunteers
suggest that pasireotide-associated hyperglycemia is due to
reduced secretion of glucagon-like peptide (GLP)-1, glucose-
dependent insulinotropic polypeptide, and insulin; however, it
is associated with intact postprandial glucagon secretion.
Individual patients’ results demonstrate effective hyperglyce-
mia management by following standard guidelines for the
treatment of diabetes mellitus with individual adaptation to the
specific underlying pathophysiology, i.e., preferential use of
GLP-1 based-medications. Patients on pasireotide treatment
should be monitored for changes in glucose metabolism and
hyperglycemia. Diabetes mellitus should be managed by ini-
tiation of medical therapy with metformin and staged treatment
intensification with a dipeptidyl peptidase-4 inhibitor, with a
switch to a GLP-1 receptor agonist and initiation of insulin, as
required, to achieve and maintain glycemic control. Further
research into hyperglycemia following pasireotide treatment
will help refine the optimal strategy in Cushing’s disease.
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Introduction
Cushing’s disease is a severe clinical condition caused
by a pituitary adenoma hypersecreting adrenocorticotropic
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hormone (ACTH). The persistently high levels of ACTH
lead to chronic hypersecretion of cortisol by the adrenal
glands, which negatively affects many tissues and organs in
the body. Cushing’s disease accounts for [70 % of the
causes of endogenous chronic hypercortisolism, other causes
include ectopic ACTH secretion by tumors, adrenal ade-
noma or carcinoma, macronodular or micronodular adrenal
hyperplasia, and, more rarely, primary pigmented nodular
adrenocortical disease and McCune–Albright syndrome [1].
Cushing’s disease is a rare disorder associated with sub-
stantial morbidity and mortality. It has an annual incidence
of 1.2–2.4 cases per million population [2, 3] and a preva-
lence of 29.1 per million [3]. The effects of Cushing’s disease
include metabolic and cardiovascular complications, osteo-
porosis and other bone alterations, kidney stones, autoim-
mune diseases, and susceptibility to opportunistic infections
[4–15]. Mortality in patients with active Cushing’s disease is
4-times higher than in age- and sex-matched controls [3, 16].
The goals for treating Cushing’s disease are the reversal or
amelioration of clinical symptoms by the normalization of
cortisol levels to achieve minimal morbidity while incurring
the fewest side effects possible. This can be realized by the
removal of the tumor mass (while preserving pituitary
function) and inhibition of tumor growth to achieve long-
term control without recurrence. Several interventions exist
to treat Cushing’s disease, including surgery, radiotherapy,
and medical therapy. Although initial surgery is most fre-
quently used as the first-line option, it often fails [1, 17].
Radiotherapy may be an option when initial surgery is
unsuccessful. However, therapeutic effects are often delayed
and become apparent sometimes only after many years [18].
Also, radiotherapy may have side effects including partial or
complete pituitary deficiency [19]. Medical therapies can be
useful in patients with persistent disease or recurrence after
surgery, but many of the drugs applied have limited effects or
are not approved for Cushing’s disease [17, 20]. Adrenostatic
medical therapies, including ketoconazole, metyrapone,
mitotane, and etomidate, may also be used for Cushing’s
disease [17, 20]. Novel therapies directed to reduce cortisol
levels or cortisol biological action such as 11-beta-hydrox-
ylase inhibitors or blockers of the glucocorticoid receptor are
also in development [21, 22].
Pasireotide (Signifor; Novartis Pharma AG, Basel,
Switzerland) is the first medical therapy approved in the
European Union to treat adult patients with Cushing’s
disease for whom surgery is not an option or for whom
surgery has failed. Pasireotide is the only medical treat-
ment targeting the pituitary adenoma and has demonstrated
long-term effectiveness for the biochemical control and
clinical improvement of patients with Cushing’s disease
[23, 24]. It was approved based on the results of a pivotal
phase III study [23]. In this study, 26.3 % of patients
treated with pasireotide 900 lg twice daily and 14.6 %
treated with pasireotide 600 lg twice daily achieved nor-
mal urinary free cortisol (UFC) levels at month 6 without
dose escalation, and 50 of 103 patients had a substantial
reduction (either normalization or at least reduction from
baseline) in the UFC levels at 6 months [23]. In patients
treated with pasireotide 900 lg twice daily and who had
baseline UFC levels between 1.5- and 2-times the upper
limit of normal, half achieved normalization of UFC [23].
Clinical signs and symptoms of Cushing’s disease
improved in most patients in this study, including a sig-
nificant reduction in body weight, systolic- and diastolic-
blood pressure, and low-density lipoprotein cholesterol
levels, with a reduction in mean UFC [23].
Hyperglycemia secondary to hypercortisolism
Patients with Cushing’s disease are at a high risk of devel-
oping impaired glucose tolerance (IGT) and manifest diabetes
secondary to hypercortisolism. A number of pathophysio-
logical mechanisms underlie glucocorticoid-induced diabetes
development in patients with Cushing’s disease (Fig. 1) [25,
26]. In general, chronic hypercortisolism blocks or impedes
the action of insulin on peripheral tissues, such as liver, muscle
and adipose tissue, leading to increased insulin resistance, and
it partially inhibits insulin release by the pancreatic beta-cells.
In particular, the glucocorticoid excess of patients with
Cushing’s disease has a number of effects on glucose
metabolism in hepatic tissue. These effects may be direct, such
as stimulating gluconeogenesis through the induction of
expression of essential enzymes [e.g., glucose transporter type
4, protein phosphatase 1, glycogen synthase kinase 3, and
glycogen synthase (Fig. 1 provides an overview of the path-
ophysiological mechanisms of glucocorticoid-induced dia-
betes)] stimulating lipolysis and proteolysis with production
of free fatty acids and amino acids which are substrates for
gluconeogenesis, or the potentiation of hormone actions
(especially glucagon) involved in glucose metabolism. Or
they may be indirect, through the inhibition of insulin sensi-
tivity by the depletion of glycogen storage in the liver [27–30].
The cortisol excess in patients with Cushing’s disease also
leads to increased appetite and other central effects. Moreover,
glucocorticoids induce pancreatic beta-cell dysfunction by
inhibiting several signaling pathways and interfering at sev-
eral steps in the insulin signaling cascade, particularly those
that involve glucose cycling, glucose 6 phosphate, and protein
kinase A and C activation (Fig. 1) [25, 26], all which may
contribute to the risk of hyperglycemia secondary to hyper-
cortisolism. Over time, patients are therefore likely to develop
a disturbance of glucose homeostasis. In a recent study, the
prevalence of IGT was 27 % in patients with Cushing’s dis-
ease and adrenal adenomas compared with 10 % in matched
controls (P \ 0.001) [31], which may develop further to
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manifest diabetes mellitus induced by the endocrine disease
[32]. According to American Diabetes Association (ADA)
classification, this type of diabetes can be classified under
‘‘Other specific types of diabetes due to other causes’’ or type 3
diabetes mellitus [32]. This diabetes should be managed in a
similar way to type 2 diabetes mellitus (T2DM).
Generally, 40–45 % of patients with Cushing’s disease
have been reported to develop diabetes and a further 10–30 %
of patients have IGT [25, 33]. This compares with a phase II
study which found that 5 % of patients with acromegaly
treated with pasireotide developed diabetes, in addition to 7 %
of patients showing increased blood glucose levels, and 5 %
increased glycated hemoglobin (HbA1C) levels [34]. How-
ever, these figures may be an under-estimation of the true
number of patients affected as specific testing of diabetes
mellitus is not always performed in these patients.
Hyperglycemia secondary to pasireotide treatment
Although the general safety profile of pasireotide in the
pivotal study was consistent with first-generation somato-
statin analogs (octreotide and lanreotide), hyperglycemia
was observed in the majority of patients, with hypergly-
cemia-related adverse events reported in 72.8 % of patients
[23]. Adverse events such as hyperglycemia and diabetes
mellitus classified as grade 3 and 4 (according to the
National Cancer Institute Common Terminology for
Adverse Events version 3.0 [35]) occurred in up to 20 % of
patients [23]. Levels of glucose and HbA1C increased soon
after the initiation of pasireotide treatment, and remained
elevated throughout the treatment period in this study.
The pathophysiology of hyperglycemia secondary to
pasireotide treatment, and methods for its management were
investigated in two mechanistic studies in healthy volunteers
[36]. These investigations have demonstrated that pasireo-
tide administered over a short 8-day period decreases
secretion of insulin by the beta-cell and intestinal secretion
of glucagon-like peptide (GLP)-1 and glucose-dependent
insulinotropic peptide, possibly through somatostatin
receptor mediated effects on pancreatic beta-cells and ente-
ro-endocrine cells [36]. Hepatic and peripheral insulin
sensitivity remains unchanged [36]. This diminished insu-
linotropic incretin effect may further contribute to the
reduced insulin secretion that was observed. The studies
suggest that in healthy volunteers dipeptidyl peptidase
(DPP)-4 inhibitors (e.g., sitagliptin, vildagliptin, saxagliptin,
linagliptin) and GLP-1 receptor agonists (e.g., liraglutide,
exenatide) may be the most effective agents for reducing
pasireotide-associated hyperglycemia [36].
Fig. 1 Pathophysiological mechanisms of glucocorticoid-induced
diabetes. Adapted with permission from Refs. [25]  2011 Elsevier;
and [26]  2009 John Wiley and Sons. AC adenyl cyclase, Ach
acetylcholine, ATP adenosine triphosphate, cAMP cyclic adenosine
monophosphate, DAG diacylglycerol, 4E-BP1 eIF4E-binding protein
1, G6P glucose-6-phosphatase, G i G-coupled inhibitory protein, GC
glucocorticoid, GK glucokinase, GLUT2 glucose transporter 2,
GLUT4 glucose transporter 4, GS glycogen synthase, GSK-3 glycogen
synthase kinase-3, HK hexokinase, IFG-1 insulin-like growth factor-
1, IP3 inositol triphosphate, Kv15 voltage-dependent K channel, IR
insulin receptor, IRS-1 insulin receptor substrate-1, mTOR mamma-
lian target of rapamycin, MuRF-1 muscle ring finger-1, PI3-K
phosphatidylinositol-3 kinase, PIP2 phosphatidylinositol biphosphate,
PKA protein kinase A, PKB protein kinase B, PKC protein kinase C,
PLC phospholipase C, PP-1 protein phosphatase-1, SGK-1 serum-
and glucocorticoid inducible kinase-1, S6K1 protein S6 kinase 1
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On February 23, 2012 a group of ten European experts in
the field of pituitary diseases and diabetes mellitus met at an
Advisory Board meeting in Munich, Germany, to propose an
approach to the management of hyperglycemia in patients
with Cushing’s disease treated with pasireotide. This paper
provides medical expert recommendations on the monitoring
and treatment of hyperglycemia in patients with Cushing’s
disease. The recent approval of pasireotide as a medical
therapy for patients with persistent or recurrent Cushing’s
disease for whom surgery is not an option or for whom surgery
has failed renders these recommendations especially timely.
Methods
These recommendations were prepared from the outcomes
of the Advisory Board meeting and this article presents a
summary of the discussions of the experts.
Results
Expert recommendations
For monitoring patients with Cushing’s disease treated
with pasireotide
The results of the pivotal phase III study of pasireotide in
patients with Cushing’s disease demonstrated that the
majority of patients treated with pasireotide will develop
hyperglycemia [23]. Therefore, all patients treated with
pasireotide should be monitored for the development of
IGT or manifest diabetes mellitus. Current definitions used
by the ADA for the diagnosis of manifest diabetes are an
HbA1C level of C6.5 %, a fasting plasma glucose level of
C126 mg/dL (7.0 mmol/L), a 2-h plasma glucose level of
C200 mg/dL (11.1 mmol/L) during an oral glucose toler-
ance test; or in patients with classic symptoms of hyper-
glycemia or hyperglycemic crisis, a random plasma
glucose level of C200 mg/dL (11.1 mmol/L) [32].
Patients with normal glucose metabolism prior to
pasireotide therapy should self-monitor their fasting and
postprandial glucose levels by taking several blood glucose
measurements per day (e.g., before and 2 h after breakfast,
lunch, and dinner). They should do so twice in the first
week and once weekly thereafter. Patients with impaired
fasting glycemia (IFG) and/or IGT, and patients with dia-
betes under treatment, must be closely monitored on a daily
basis at the start of treatment with pasireotide and, if
needed, treatment shall be adjusted or changed in order to
control the new level of glycemia. Their treating physician
should follow-up closely (e.g., after 1, 2, and 4 weeks) to
assess the emergence of any hyperglycemia and initiate
appropriate therapy.
For treating hyperglycemia secondary to pasireotide
therapy in patients with Cushing’s disease
Treatment for patients with Cushing’s disease, whether
they present with IFG and/or IGT or diabetes, or develop
Fig. 2 Recommendations on
the monitoring and treatment of
hyperglycemia in patients with
Cushing’s disease treated with
pasireotide. In case patients fail
to control glucose levels with
GLP-1 agonists, as stated in the






fasting glycemia, IGT impaired
glucose tolerance, NGT normal
glucose tolerance, OAD oral
antidiabetic drugs, SMBG self-
monitoring of blood glucose
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hyperglycemia secondary to treatment with pasireotide,
should be based on the currently recommended treatment
algorithms for T2DM. Thus, individually tailored glycemic
targets of HbA1C level of\7.0–7.5 % (\53–58 mmol/mol)
are appropriate unless the treating clinician perceives a risk
due to hypoglycemia, or if the patient is unlikely to survive
long enough to be at risk of complications. Medical treat-
ment should include dietary modification, exercise, and
education. In patients with evidence of insulin resistance,
medication should be initiated with metformin as the first-
line therapy unless contraindicated or not well tolerated
(Fig. 2) [33, 37].
As pasireotide-related hyperglycemia is associated with
both decreased insulin secretion and a reduced incretin
response [34], anti-hyperglycemic treatment in patients
with Cushing’s disease treated with pasireotide should
preferentially address these two pathophysiological mech-
anisms. If control of glycemia is not achieved or main-
tained with metformin alone, combination therapy with
agents targeting the incretin-pathway is recommended [36].
Based on the preliminary data mentioned above [36], it is
suggested that in hyperglycemia secondary to pasireotide
treatment, metformin in combination with a GLP-1-based
treatment option may be specifically advantageous (Fig. 2).
Therefore, in a first step combination, therapy with a DPP-
4 inhibitor may be established. In addition, to target the
specific pathophysiology of hyperglycemia secondary to
pasireotide treatment, this combination provides the spe-
cific advantages of a low hypoglycemic potential together
with a neutral effect on body weight. Although combina-
tion therapies of metformin with sulfonylureas and/or
pioglitazone may also be possible theoretically, these are
not recommended as sulphonylureas stimulate insulin
secretion in a glucose-independent manner and, therefore,
are associated with a substantial risk of hypoglycemia and
weight gain. Furthermore, treatment failure due to a decline
of pancreatic beta-cell function may occur more rapidly
with sulphonylurea therapy. Pioglitazone primarily targets
insulin resistance and does not, therefore, represent a
pathophysiologically-oriented treatment option for hyper-
glycemia secondary to pasireotide therapy. Moreover,
pioglitazone treatment has been associated with an increase
in body weight, fluid retention, and bone fractures—all side
effects that are most unwanted in Cushing’s disease
patients [38].
If glycemic targets are not reached with the metformin
plus DDP-4 inhibitor combination, the DPP-4 inhibitor
may be replaced by a GLP-1 receptor agonist. These GLP-
1 analogs have demonstrated an HbA1C-lowering effect
that is superior to that of DPP-4 inhibitors without increase
of hypoglycemia risk. In addition, they provide the
potential to reduce body weight, which is desirable in
Cushing’s disease. If hyperglycemia secondary to
pasireotide treatment in patients with Cushing’s disease
remains uncontrolled by these combinations, establishing
insulin therapy together with maintained metformin treat-
ment may be necessary. In these cases, initial combination
therapy of metformin with a once-daily application of a
long-acting basal insulin analog (either glargine or detemir
since they have similar efficacy on glucose target [39])
targeting levels of fasting plasma glucose considered
acceptable by the treating physician, may be the first
option. If the individual HbA1C targets are not met or the
postprandial glucose levels are high with this basal insulin-
supported anti-diabetic therapy, then prandial insulin
therapy also has to be finally established.
These recommendations are supported by similar pro-
posals on the management of hyperglycemia in Cushing’s
disease developed from a review of the existing literature
[40]. Reznik et al. suggest that patients should be tested for
impaired glucose regulation before initiating treatment
with pasireotide. They should be monitored for glycemic
control on initiation of pasireotide and also as part of
regular follow-ups and, if glycemic control deteriorates
during pasireotide therapy, they should be treated with
antidiabetic therapy as appropriate [40].
Further research
A study of patients with Cushing’s disease who perform
regular monitoring of blood glucose would provide infor-
mation to help stratify patients by risk of hyperglycemia
and assist the development of specific guidelines for
managing this risk in the future. At this point, however, it
seems prudent to apply a similar clinical risk estimation for
the development of glycemic disorders in patients with
Cushing’s disease as is standard in patients at-risk for
classical T2DM. This involves assessing features of the
metabolic syndrome, such as visceral obesity, concomitant
dyslipoproteinemia and hypertension, and familial back-
ground for metabolic disease. Whether validated diabetes
risk questionnaires such as the ones developed from the
Study to Prevent Non-Insulin Dependent Diabetes Mellitus
(STOP-NIDDM) and the Finnish Cardiovascular Risk
Factor (FINDRISK) [41, 42], may help to identify patients
at risk in the setting of Cushing’s disease is unknown.
Significant progress in understanding the fundamental
pathophysiology of hyperglycemia secondary to pasireo-
tide treatment has been made since the phenomenon
was first recognized. However, further research on how
pasireotide influences insulin biosynthesis and secretion,
and insulin sensitivity in patients with Cushing’s disease
will help to define the optimum treatment strategies for
hyperglycemia in this difficult to manage condition.
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Although metformin followed by the addition of a DPP-
4 inhibitor, with a switch from the DPP-4 inhibitor to a
GLP-1 receptor agonist or insulin therapy as required to
maintain glycemic targets, is suggested as a suitable
treatment of hyperglycemia secondary to pasireotide ther-
apy, the efficacy of anti-hyperglycemic regimens needs to
be further explored in a clinical trial in patients with
Cushing’s disease.
Summary
Patients with Cushing’s disease have a high risk of
hyperglycemia due to the long-term effect of hypercorti-
solism, and emergence or worsening of hyperglycemia is
frequently observed secondary to pasireotide treatment.
However, mechanistic studies and individual observations
in patients with Cushing’s disease suggest that pasireotide-
related hyperglycemia responds to anti-diabetic agents
following similar protocols recommended for the treatment
of T2DM, with a specific focus on GLP-1-based medica-
tions. More research is necessary to confirm these results
and to refine the recommendations for diagnosis and
treatment of hyperglycemia in patients with Cushing’s
disease in order to optimize their management.
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